Multiple inflammatory and immune pathway proteins

The term 'Multiple inflammatory and immune pathway proteins' does not refer to a single molecular target but rather describes a broad collective of proteins involved in the orchestration of the immune response and inflammatory signaling. This group encompasses various cytokines (e.g., TNF, IL-1, IL-6), chemokines, cell surface receptors, and intracellular signaling molecules such as Janus kinases (JAKs) and transcription factors like NF-κB (Nature Reviews Drug Discovery, 2017). These proteins play critical roles in both innate and adaptive immunity, facilitating the recruitment and activation of immune cells to sites of injury or infection (Cell, 2010). Dysregulation of these pathways is a hallmark of numerous pathological conditions, including rheumatoid arthritis, inflammatory bowel disease, and various autoimmune disorders, where chronic overactivation leads to tissue damage (The Lancet, 2016). Broad-spectrum therapeutic agents, such as glucocorticoids or multi-kinase inhibitors, often impact several of these proteins simultaneously to dampen systemic inflammation. Because this classification is overly broad and lacks a specific UniProt identifier or singular biochemical function, it is generally considered an 'incorrect' or non-specific target designation for drug discovery and molecular profiling purposes.

Other names

Inflammatory mediatorsImmune pathway proteinsPro-inflammatory cytokines and signaling molecules

Drugs targeting these pathways typically act through broad immunosuppression or by inhibiting multiple signaling cascades (e.g., NF-κB, JAK-STAT, or MAPK) to reduce the production and activity of various inflammatory mediators.